What a 120-Day Scalp Study Can Show

Reading a single-arm study

KilgourMD and N1 Life announced a scalp-health partnership in January 2026. A separate KilgourMD dual-serum study, published in the Journal of Drugs in Dermatology, now provides a chance to look closely at the evidence behind one existing product system. The paper does not test N1 Life’s delivery technology.^{[1, 2]}

Repeated measures, one treatment arm

The prospective study enrolled 43 women with female-pattern hair loss and followed use of KilgourMD’s two serums for 120 days. Researchers measured shedding by standardized combing and a modified hair-wash test, then used dermatologist assessments and photographs to examine hair appearance. Visits occurred at baseline and days 45, 90 and 120.^[1]

The mean combing-test shedding count was 60.3% lower at day 120 than at baseline. That is a change observed within the treated group. With no randomized comparison group, the study cannot separate a product effect from other influences on shedding over time.^[1]

What the next comparison needs

The study adds structured observations for a particular dual-serum regimen. It does not establish how either serum works, which ingredient contributed most, or whether a different regimen would produce the same result. A controlled comparison would be needed to address those questions.

KilgourMD’s published partnership with N1 concerns future scalp-health formulations. The JDD paper should therefore be read as evidence about the system studied, not as a clinical validation of N1’s peptide delivery work.^{[1, 2]}

Sources

1. González Fernández D, Quinn C, Alhayek S, et al. Efficacy of a Dual-Serum Cosmetic System in Women With Female Pattern Hair Loss. Journal of Drugs in Dermatology. 2026;25(6):83251s3–83251s10. doi:10.36849/JDD.83251.
2. KilgourMD. KilgourMD Announces Exclusive Partnership With N1 Life to Bring Peptide-Based Delivery Technology to Scalp Health. January 7, 2026.